Comparison between Infinium Pharmachem IPO and Sotac Pharmaceuticals IPO.
Infinium Pharmachem IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Sotac Pharmaceuticals IPO is a SME Bookbuilding proposed to list at NSE SME.
| Infinium Pharmachem IPO | Sotac Pharmaceuticals IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Fixed Price | Bookbuilding |
| Listing At | NSE SME | NSE SME |
| Lead Managers | Swastika Investmart Ltd. | Beeline Capital Advisors Pvt.Ltd. |
| Registrar | Bigshare Services Pvt.Ltd. | Kfin Technologies Ltd. |
| Market Maker | Swastika Investmart Ltd. | Sunflower Broking Pvt.Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Infinium Pharmachem IPO is up to ₹23.99 Cr whereas the issue size of the Sotac Pharmaceuticals IPO is up to ₹31.64 Cr. The final issue price of Infinium Pharmachem IPO is ₹135.00 per share and of Sotac Pharmaceuticals IPO is ₹111.00 per share.
| Infinium Pharmachem IPO | Sotac Pharmaceuticals IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹105.00 per share | |
| Issue Price (Upper) | ₹111.00 per share | |
| Issue Price (Final) | ₹135.00 per share | ₹111.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹13.50 per share | |
| Market Lot Size | 1000 shares | 1200 shares |
| Fresh Issue Size | 17,81,000 shares | 28,50,000 shares |
| Fresh Issue Size (Amount) | up to ₹23.99 Cr | up to ₹31.64 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 17,81,000 shares | 28,50,000 shares |
| Issue Size Total (Amount) | up to ₹23.99 Cr | up to ₹31.64 Cr |
Infinium Pharmachem IPO opens on Mar 31, 2023, while Sotac Pharmaceuticals IPO opens on Mar 29, 2023. The closing date of Infinium Pharmachem IPO and Sotac Pharmaceuticals IPO is Apr 05, 2023, and Apr 03, 2023, respectively.
| Infinium Pharmachem IPO | Sotac Pharmaceuticals IPO | |
|---|---|---|
| Anchor Bid Date | Mar 28, 2023 | |
| Issue Open | Mar 31, 2023 | Mar 29, 2023 |
| Issue Close | Apr 05, 2023 | Apr 03, 2023 |
| Basis Of Allotment (Tentative) | Apr 11, 2023 | Apr 10, 2023 |
| Initiation of Refunds (Tentative) | Apr 12, 2023 | Apr 11, 2023 |
| Credit of Share (Tentative) | Apr 13, 2023 | Apr 12, 2023 |
| Listing date (Tentative) | Apr 17, 2023 | Apr 13, 2023 |
| Anchor Lockin End date 1 | May 10, 2023 | |
| Anchor Lockin End date 2 | Jul 09, 2023 |
Infinium Pharmachem IPO P/E ratio is 7.83, as compared to Sotac Pharmaceuticals IPO P/E ratio of 132.14.
| Infinium Pharmachem IPO | Sotac Pharmaceuticals IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 100 | 84.63 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 73.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 7.83 | 132.14 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹93.93 Cr. | ₹122.66 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 43.85 | 53.1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 72 | 68.34 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 2.91 | 1.12 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹54.13 | ₹3.58 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 46.61 | 43.47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Infinium Pharmachem IPO Retail Individual Investors (RII) are offered 8,70,000 shares while in Sotac Pharmaceuticals IPO retail investors are offered 8,70,000 shares. Qualified Institutional Buyers (QIB) are offered in Infinium Pharmachem IPO and 5,70,000 shares in Sotac Pharmaceuticals IPO.
| Infinium Pharmachem IPO | Sotac Pharmaceuticals IPO | |
|---|---|---|
| Anchor Investor Reservation | 8,53,200 shares | |
| Market Maker Reservation | 94,000 shares | 1,50,000 shares |
| QIB | 5,70,000 shares | |
| NII | 8,70,000 shares | 4,28,400 shares |
| RII | 8,70,000 shares | 9,98,400 shares |
| Employee | 41,000 shares | |
| Others | ||
| Total | 17,81,000 shares | 28,50,000 shares |
Infinium Pharmachem IPO subscribed 1.92x in total, whereas Sotac Pharmaceuticals IPO subscribed 1.60x.
| Infinium Pharmachem IPO | Sotac Pharmaceuticals IPO | |
|---|---|---|
| QIB (times) | 1.00x | |
| NII (times) | 1.94x | 4.04x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 2.00x | 0.91x |
| Employee (times) | 1.29x | |
| Other (times) | ||
| Total (times) | 1.92x | 1.60x |
